Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Ney Carter Borges: Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling
Ney Carter Borges/LinkedIn
Apr 17, 2026, 16:51

Ney Carter Borges: Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling: A Translational Genetic Insight

The persistent burden of cardiovascular disease (CVD), despite advances in lipid-lowering and preventive therapies, underscores the importance of residual risk pathways – particularly lipoprotein(a) [Lp(a)] and systemic inflammation.

This study elegantly bridges these two domains by leveraging Mendelian randomization to simulate lifelong exposure to reduced Lp(a) levels and attenuated interleukin-6 (IL-6) signalling, offering a quasi-causal perspective on their individual and combined effects.

Analyzing data from over 408,000 individuals in the UK Biobank, the investigators demonstrate that genetically lower Lp(a) is consistently associated with a significant reduction in multiple cardiovascular outcomes, including coronary heart disease (CHD), stroke, heart failure, and peripheral arterial disease.

Importantly, this protective effect remains stable regardless of the underlying inflammatory milieu, suggesting that Lp(a)-mediated risk operates through both inflammatory and non-inflammatory mechanisms.

In parallel, reduced IL-6 signalling – representing a more proximal and biologically relevant inflammatory axis than hsCRP – was independently associated with lower risks of CHD, atrial fibrillation, and aortic aneurysm.

The most compelling finding, however, emerges from the factorial analysis: the combination of lower Lp(a) and reduced IL-6 signalling produced a markedly greater reduction in CHD risk (OR ~0.25), consistent with an additive, rather than synergistic, effect .

This nuanced distinction is clinically meaningful.

It implies that these pathways contribute independently to atherogenesis and that dual targeting may address complementary mechanisms – lipid-driven plaque formation and inflammation-driven plaque instability.

Observational analyses further reinforce this concept, showing the lowest event rates among individuals with both low Lp(a) and low IL-6 levels.

From a translational standpoint, these findings anticipate a future paradigm in which combined therapies—such as RNA-based Lp(a) inhibitors alongside anti–IL-6 agents—may redefine residual risk management.

Yet, caution is warranted: genetic proxies reflect lifelong exposure, and ongoing randomized trials will be critical to confirm the magnitude and timing of benefit in clinical practice.

In essence, this study shifts the conversation from ‘which pathway matters most’  to ‘how multiple pathways can be strategically integrated’ to achieve deeper cardiovascular protection.”

Ney Carter Borges: Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling

Stay updated  with Hemostasis Today.

Cardiovascular Disease Coronary Heart Disease Health Hematology Hemostasis Hemostasis News Hemostasis Today IL-6 Lipoprotein a Lipoprotein(a) Ney Carter Borges
NewsFeed